Table 3.
Effect of SRF solution, GA solution, SRF and GA solution, SRF and GA-loaded NLCs on the number of rats, number of nodules and average number of nodules bearing rats.
| S. No | Groups | Number of rats with nodules/ Number of rats | Total Number of Nodules | Relative size (% of number size) |
||
|---|---|---|---|---|---|---|
| ≤1mm | <3mm > 1 mm | ≥3mm | ||||
| 1 | Normal control | 0/6 | 0 | 0 | 0 | 0 |
| 2 | DEN control receiving SRF (50 mg/kg) 5 mL/kg/day for 14 weeks | 5/6 | 214 | 101 | 61 | 52 |
| 3 | DEN control | 6/6 | 250 | 115 | 75 | 60 |
| 4 | DEN control group of rats administered with GA (50 mg/kg) | 6/6 | 222 | 110 | 65 | 47 |
| 5 | DENcontrol rats administered withSRF and GA (25 mg/kg each of drug) | 4/6 | 132 | 52 | 45 | 35 |
| 6 | DEN control administered with SRF cum GA loaded NLC (25 mg/kg each of drug dose) single dose 5 mL/kg/day p.o. for 14 weeks | 1/6 | 20 | 20 | 0 | 0 |
Group I did not show the any sign of hepatic nodules and VI did show least sign of hepatic nodules among group (SRF; Sorafenib GA; Ganoderic Acid: DEN; Diethyl nitrosamine: NLC; Nano lipidic carrier).